ASH Clinical News September 2017 New | Page 53

Check out the new and improved
ASHClinicalNews.org!
SLEEKER
DESIGN,
EASIER
NAVIGATION
FACTOR REPLACEMENT MIRRORS
THE PROTECTION WITHIN
QUICKLY FIND THE
LATEST NEWS ...
AND EASILY BROWSE
THE PRINT ISSUE!
For your patients with Hemophilia A,
Factor treatment has a long history of results. 1
It temporarily replaces what’s missing and is regulated
by the natural hemostatic process to form a proper clot. 2-5
Brought to you by Shire, dedicated to pursuing
advancements in hemophilia for more than 60 years.
Explore an established treatment option
in hemophilia
References: 1. Franchini M, Mannucci PM. The history of hemophilia. Semin Thromb Hemost. 2014;40:571-576. 2. Peyvandi F, Garagiola I, Young G. The past and future
of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388:187-197. 3. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in
view of its structure and function. Blood. 1998;92(11):3983-3996. 4. Antovic A, Mikovic D, Elezovic I, Zabczyk M, Hutenby K, Antovic JP. Improvement of fibrin clot structure
after factor VIII injection in haemophilia A patients treated on demand. Thromb Haemost. 2013;111(4):656-661. 5. Hvas AM, Sørensen HT, Norengaard L, Christiansen K,
Ingerslev J, Sørensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost.
2007;5:2408-2414.
©2017 Shire US Inc., Lexington, MA 02421.
All rights reserved. 1-800-828-2088.
SHIRE and the Shire Logo are registered trademarks of
Shire Pharmaceutical Holdings Ireland Limited or its affiliates.
S31962 05/17